The Food Effect on Pharmacokinetics of Fixed Dose Combination of Gemigliptin/Dapagliflozin/Metformin in Healthy Volunteers
← catalyst calendarSponsored by LG Chem (industry) · 051910.KS — their whole pipeline →.
Phase
Phase 1
Status
Not yet recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
28estimated
Sites
1
Country
Thailand
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-07-01 | estimated | When the study began enrolling |
| Primary completion | 2026-07-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-07-31 | estimated | The whole study's end, after follow-up |
| First posted | 2026-02-09 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Healthy
- Fasting
- Fed
Intervention
- Drug: Fixed-dose combination of gemigliptin/dapagliflozin/metformin 50/10/1000 mg
Primary outcomes
what the primary-completion date above is the date OFThe plasma concentration of Gemigliptin, Dapagliflozin and Metformin.
measured 17 times up to 72 hours after IP administration
The plasma concentration of Gemigliptin, Dapagliflozin and Metformin.
measured 17 times up to 72 hours after IP administration
The plasma concentration of Gemigliptin, Dapagliflozin and Metformin.
measured 17 times up to 72 hours after IP administration
Permalink · 051910.KS's whole pipeline · Catalyst calendar · Every registered study · What changed